Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2021 Filed May 21, 2021 21:32 UTC |
Dolsten MikaelDirector
|
GrantNonstatutory Stock Option (right to buy) · Derivative | 23,900 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001209191-21-035025 · doc4.xml · derivative · entry 1 Dolsten Mikael · CIK 0001437590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Underlying: Common Stock · 23,900 shares Expires 2031-05-20 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 21, 2022 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. (the "Issuer"), provided that the reporting person continues to serve as a director of the Issuer through such date. Read SEC document |
| May 21, 2021 Filed May 21, 2021 21:33 UTC |
Greene Barry EDirector
|
GrantNonstatutory Stock Option (right to buy) · Derivative | 23,900 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001209191-21-035026 · doc4.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Underlying: Common Stock · 23,900 shares Expires 2031-05-20 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 21, 2022 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. (the "Issuer"), provided that the reporting person continues to serve as a director of the Issuer through such date. Read SEC document |
| May 21, 2021 Filed May 21, 2021 21:35 UTC |
PAKIANATHAN DEEPIKADirector
|
GrantNonstatutory Stock Option (right to buy) · Derivative | 23,900 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001209191-21-035030 · doc4.xml · derivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Underlying: Common Stock · 23,900 shares Expires 2031-05-20 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 21, 2022 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. (the "Issuer"), provided that the reporting person continues to serve as a director of the Issuer through such date. Read SEC document |
| May 21, 2021 Filed May 21, 2021 21:31 UTC |
BOHLIN GAREN GDirector
|
GrantNonstatutory Stock Option (right to buy) · Derivative | 23,900 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001209191-21-035024 · doc4.xml · derivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Underlying: Common Stock · 23,900 shares Expires 2031-05-20 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 21, 2022 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. (the "Issuer"), provided that the reporting person continues to serve as a director of the Issuer through such date. Read SEC document |
| May 21, 2021 Filed May 21, 2021 21:36 UTC |
Schor ChenDirector
|
GrantNonstatutory Stock Option (right to buy) · Derivative | 23,900 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001209191-21-035031 · doc4.xml · derivative · entry 1 Schor Chen · CIK 0001340875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Underlying: Common Stock · 23,900 shares Expires 2031-05-20 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 21, 2022 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. (the "Issuer"), provided that the reporting person continues to serve as a director of the Issuer through such date. Read SEC document |
| May 21, 2021 Filed May 21, 2021 21:35 UTC |
Oliger Christy J.Director
|
GrantNonstatutory Stock Option (right to buy) · Derivative | 23,900 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001209191-21-035028 · doc4.xml · derivative · entry 1 Oliger Christy J. · CIK 0001822092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Underlying: Common Stock · 23,900 shares Expires 2031-05-20 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 21, 2022 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. (the "Issuer"), provided that the reporting person continues to serve as a director of the Issuer through such date. Read SEC document |
| May 21, 2021 Filed May 21, 2021 21:34 UTC |
Mirza Mansoor RazaDirector
|
GrantNonstatutory Stock Option (right to buy) · Derivative | 23,900 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001209191-21-035027 · doc4.xml · derivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Underlying: Common Stock · 23,900 shares Expires 2031-05-20 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 21, 2022 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. (the "Issuer"), provided that the reporting person continues to serve as a director of the Issuer through such date. Read SEC document |
| May 07, 2021 Filed May 11, 2021 12:58 UTC |
Shah JatinEVP, Chief Medical Officer
|
PurchaseCommon Stock | 23,250 | $8.60 | $199,991.85 |
DisclosureSEC source: 0001209191-21-031481 · doc4.xml · nonDerivative · entry 1 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,802 F1 · price: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $8.5850 to $8.61, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 861 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on April 30, 2021. Read SEC document |
| May 06, 2021 Filed May 10, 2021 23:57 UTC |
BOHLIN GAREN GDirector
|
PurchaseCommon Stock | 4,000 | $7.82 | $31,280.00 |
DisclosureSEC source: 0001209191-21-031437 · doc4.xml · nonDerivative · entry 1 BOHLIN GAREN G · CIK 0001254705 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
| May 03, 2021 Filed May 5, 2021 01:06 UTC |
Paulson Richard A.Director · President and CEO
|
GrantStock Option (right to buy) · Derivative | 559,800 | $0.00 Strike: $9.44 | $0.00 |
DisclosureSEC source: 0001209191-21-030166 · doc4.xml · derivative · entry 2 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 559,800 Underlying: Common Stock · 559,800 shares Expires 2031-05-02 F2 · derivative.exercise_date: This option was granted on May 3, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on May 3, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 03, 2021 Filed May 5, 2021 01:06 UTC |
Paulson Richard A.Director · President and CEO
|
GrantCommon Stock | 373,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030166 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373,200 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 25% of the shares on May 3, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 18, 2021 Filed Mar 23, 2021 11:48 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
SaleCommon Stock | 4,000 | $12.39 | $49,552.80 |
DisclosureSEC source: 0001209191-21-022486 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714,826 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.29 to $12.56, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 18, 2021 Filed Mar 23, 2021 11:50 UTC |
Shacham SharonPresident & CSO
|
SaleCommon Stock | 4,000 | $12.39 | $49,552.80 |
DisclosureSEC source: 0001209191-21-022487 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 714,826 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.29 to $12.56, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:10 UTC |
DEMAREE JOHNChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 43,177 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001209191-21-015483 · doc4.xml · derivative · entry 2 DEMAREE JOHN · CIK 0001744959 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,177 Underlying: Common Stock · 43,177 shares Expires 2031-02-24 F3 · derivative.exercise_date: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:10 UTC |
DEMAREE JOHNChief Commercial Officer
|
GrantCommon Stock | 15,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015483 · doc4.xml · nonDerivative · entry 1 DEMAREE JOHN · CIK 0001744959 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,995 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022. F2 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 15,849 newly awarded RSUs and 8,146 shares of common stock, which include 646 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2020. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:13 UTC |
Lewis TanyaEVP, Chief Reg. Affairs
|
GrantStock Option (right to buy) · Derivative | 59,968 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001209191-21-015485 · doc4.xml · derivative · entry 2 Lewis Tanya · CIK 0001451038 · EVP, Chief Reg. Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,968 Underlying: Common Stock · 59,968 shares Expires 2031-02-24 F3 · derivative.exercise_date: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:13 UTC |
Lewis TanyaEVP, Chief Reg. Affairs
|
GrantCommon Stock | 22,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015485 · doc4.xml · nonDerivative · entry 1 Lewis Tanya · CIK 0001451038 · EVP, Chief Reg. Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,401 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022. F2 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 22,013 newly awarded RSUs, 19,245 RSUs previously reported in Table II, and 4,143 shares of common stock. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:09 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 153,500 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001209191-21-015481 · doc4.xml · derivative · entry 4 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 153,500 Underlying: Common Stock · 153,500 shares Expires 2031-02-24 F4 · derivative.exercise_date: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:09 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 153,500 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001209191-21-015481 · doc4.xml · derivative · entry 3 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,500 Underlying: Common Stock · 153,500 shares Expires 2031-02-24 F4 · derivative.exercise_date: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:09 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
GrantCommon Stock | 57,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015481 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 920,152 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022. F3 · balance_after: The spouse of the reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 57,200 newly awarded RSUs, 86,500 RSUs previously reported in Table II, and 776,452 shares of common stock. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:09 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
GrantCommon Stock | 57,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015481 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718,826 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022. F2 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 57,200 newly awarded RSUs, 86,500 RSUs previously reported in Table II, and 575,126 shares of common stock. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:17 UTC |
Shah JatinEVP, Chief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 59,968 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001209191-21-015487 · doc4.xml · derivative · entry 2 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,968 Underlying: Common Stock · 59,968 shares Expires 2031-02-24 F3 · derivative.exercise_date: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:17 UTC |
Shah JatinEVP, Chief Medical Officer
|
GrantCommon Stock | 22,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015487 · doc4.xml · nonDerivative · entry 1 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,691 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022. F2 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 22,013 newly awarded RSUs, 33,887 RSUs previously reported in Table II, and 51,791 shares of common stock. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:16 UTC |
Mason MichaelSVP, CFO & Treasurer
|
GrantStock Option (right to buy) · Derivative | 59,968 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001209191-21-015486 · doc4.xml · derivative · entry 2 Mason Michael · CIK 0001514291 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,968 Underlying: Common Stock · 59,968 shares Expires 2031-02-24 F3 · derivative.exercise_date: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:16 UTC |
Mason MichaelSVP, CFO & Treasurer
|
GrantCommon Stock | 22,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015486 · doc4.xml · nonDerivative · entry 1 Mason Michael · CIK 0001514291 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,755 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022. F2 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 22,013 newly awarded RSUs, 24,450 RSUs previously reported in Table II, and 5,292 shares of common stock. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:12 UTC |
Frenkel RanEVP, Chief Dev. Officer
|
GrantStock Option (right to buy) · Derivative | 59,968 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001209191-21-015484 · doc4.xml · derivative · entry 2 Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,968 Underlying: Common Stock · 59,968 shares Expires 2031-02-24 F3 · derivative.exercise_date: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:12 UTC |
Frenkel RanEVP, Chief Dev. Officer
|
GrantCommon Stock | 22,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015484 · doc4.xml · nonDerivative · entry 1 Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,439 F1 · shares: Represents the award of Restricted Stock Units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022. F2 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 22,013 newly awarded RSUs, 36,300 RSUs previously reported in Table II, and 46,126 shares of common stock. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:09 UTC |
Shacham SharonPresident & CSO
|
GrantStock Option (right to buy) · Derivative | 153,500 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001209191-21-015482 · doc4.xml · derivative · entry 4 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 153,500 Underlying: Common Stock · 153,500 shares Expires 2031-02-24 F4 · derivative.exercise_date: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:09 UTC |
Shacham SharonPresident & CSO
|
GrantStock Option (right to buy) · Derivative | 153,500 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001209191-21-015482 · doc4.xml · derivative · entry 3 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,500 Underlying: Common Stock · 153,500 shares Expires 2031-02-24 F4 · derivative.exercise_date: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:09 UTC |
Shacham SharonPresident & CSO
|
GrantCommon Stock | 57,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015482 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 718,826 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022. F3 · balance_after: The spouse of the reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 57,200 newly awarded RSUs, 86,500 RSUs previously reported in Table II, and 575,126 shares of common stock. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:09 UTC |
Shacham SharonPresident & CSO
|
GrantCommon Stock | 57,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015482 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,152 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022. F2 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 57,200 newly awarded RSUs, 86,500 RSUs previously reported in Table II, and 776,452 shares of common stock. Read SEC document |
| February 18, 2021 Filed Feb 23, 2021 01:09 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
SaleCommon Stock | 9,495 | $14.83 | $140,822.24 |
DisclosureSEC source: 0001209191-21-012960 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 776,452 F3 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person. F4 · price: The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 18, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| February 18, 2021 Filed Feb 23, 2021 01:09 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
SaleCommon Stock | 9,495 | $14.83 | $140,822.24 |
DisclosureSEC source: 0001209191-21-012960 · doc4.xml · nonDerivative · entry 1 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,126 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 18, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| February 18, 2021 Filed Feb 23, 2021 01:11 UTC |
Frenkel RanEVP, Chief Dev. Officer
|
SaleCommon Stock | 2,887 | $14.83 | $42,817.67 |
DisclosureSEC source: 0001209191-21-012967 · doc4.xml · nonDerivative · entry 1 Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,126 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 18, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| February 18, 2021 Filed Feb 23, 2021 01:12 UTC |
Shah JatinEVP, Chief Medical Officer
|
SaleCommon Stock | 1,186 | $14.83 | $17,589.80 |
DisclosureSEC source: 0001209191-21-012968 · doc4.xml · nonDerivative · entry 1 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,791 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 18, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| February 18, 2021 Filed Feb 23, 2021 01:10 UTC |
Shacham SharonPresident & CSO
|
SaleCommon Stock | 9,495 | $14.83 | $140,822.24 |
DisclosureSEC source: 0001209191-21-012964 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 575,126 F3 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person. F4 · price: The sale price of the spouse of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 18, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| February 18, 2021 Filed Feb 23, 2021 01:10 UTC |
Shacham SharonPresident & CSO
|
SaleCommon Stock | 9,495 | $14.83 | $140,822.24 |
DisclosureSEC source: 0001209191-21-012964 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 776,452 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 18, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 23:44 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 21,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011484 · doc4.xml · derivative · entry 6 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 43,600 Underlying: Common Stock · 21,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F7 · derivative.exercise_date: On February 15, 2019, the spouse of the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F7 · derivative.expiration_date: On February 15, 2019, the spouse of the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 23:44 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 21,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011484 · doc4.xml · derivative · entry 5 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,600 Underlying: Common Stock · 21,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F6 · derivative.exercise_date: On February 15, 2019, the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F6 · derivative.expiration_date: On February 15, 2019, the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 23:44 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 21,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-011484 · doc4.xml · nonDerivative · entry 4 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 785,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 23:44 UTC |
Kauffman MichaelDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 21,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-011484 · doc4.xml · nonDerivative · entry 2 Kauffman Michael · CIK 0001364719 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 23:48 UTC |
Shah JatinEVP, Chief Medical Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 4,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011494 · doc4.xml · derivative · entry 3 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,700 Underlying: Common Stock · 4,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F4 · derivative.exercise_date: On February 15, 2019, the reporting person was granted 19,400 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F4 · derivative.expiration_date: On February 15, 2019, the reporting person was granted 19,400 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 23:48 UTC |
Shah JatinEVP, Chief Medical Officer
|
Exercise / conversionCommon Stock | 4,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-011494 · doc4.xml · nonDerivative · entry 2 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 23:47 UTC |
Frenkel RanEVP, Chief Dev. Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 9,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011490 · doc4.xml · derivative · entry 3 Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,350 Underlying: Common Stock · 9,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F4 · derivative.exercise_date: On February 15, 2019, the reporting person was granted 38,700 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F4 · derivative.expiration_date: On February 15, 2019, the reporting person was granted 38,700 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 23:47 UTC |
Frenkel RanEVP, Chief Dev. Officer
|
Exercise / conversionCommon Stock | 9,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-011490 · doc4.xml · nonDerivative · entry 2 Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 23:45 UTC |
Shacham SharonPresident & CSO
|
Exercise / conversionRestricted Stock Units · Derivative | 21,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011486 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 43,600 Underlying: Common Stock · 21,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F7 · derivative.exercise_date: On February 15, 2019, the spouse of the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F7 · derivative.expiration_date: On February 15, 2019, the spouse of the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the spouse of the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 23:45 UTC |
Shacham SharonPresident & CSO
|
Exercise / conversionRestricted Stock Units · Derivative | 21,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011486 · doc4.xml · derivative · entry 5 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,600 Underlying: Common Stock · 21,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F6 · derivative.exercise_date: On February 15, 2019, the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F6 · derivative.expiration_date: On February 15, 2019, the reporting person was granted 87,200 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 23:45 UTC |
Shacham SharonPresident & CSO
|
Exercise / conversionCommon Stock | 21,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-011486 · doc4.xml · nonDerivative · entry 4 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 584,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 23:45 UTC |
Shacham SharonPresident & CSO
|
Exercise / conversionCommon Stock | 21,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-011486 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 785,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 23:49 UTC |
Lewis TanyaEVP, Chief Reg. Affairs
|
SaleCommon Stock | 2,046 | $15.52 | $31,752.08 |
DisclosureSEC source: 0001209191-21-011496 · doc4.xml · nonDerivative · entry 1 Lewis Tanya · CIK 0001451038 · EVP, Chief Reg. Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,143 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.